CRISPR Q2 2023 net loss $77.7M; FDA accepts exa-cel BLAs with PDUFA Dec 8 for SCD

CRISPR Therapeutics AG

2023-Q2 EPS reported -$1.66 revenue$170,000,000

FDA accepted BLAs for exa-cel: Priority Review for SCD (PDUFA Dec 8, 2023), Standard Review for TDT (Mar 30, 2024).
Net loss narrowed to $77.7M from $185.8M YoY; collaboration revenue $70M from Vertex milestone.
Cash and accounts receivable $1,843M; R&D spend $101.6M, down from $123.2M Q2 2022.
Vertex licensing: $100M upfront received, $70M milestone receivable, up to $230M additional milestones.
Pipeline: CTX110/130/112/131 trials ongoing; in vivo CTX310 (ANGPTL3) enters clinic in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CRISPR Therapeutics AG reported financial results for quarter ended June 30, 2023.

Period: quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 7, 2023, CRISPR Therapeutics AG announced its financial results for the quarter ended June 30, 2023 and other business highlights.

View on SEC.gov

Browse all earnings releases →

CRISPR Therapeutics AG filing history →

Source: SEC EDGAR

accession 0000950170-23-039057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.